Overview

Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck

Status:
Recruiting

Trial end date:
2024-12-01

Target enrollment:

Participant gender:

Summary

Eligible participants with locoregional inoperable recurrence or second primary squamous cell carcinoma of the head and neck will be treated with reirradiation combined with anti-PD-1 mAb MK-3475 (generic name: pembrolizumab, trade name Keytruda®).

Phase:

Phase 2

Details

Lead Sponsor:

Dan Zandberg

Collaborator:

Merck Sharp & Dohme Corp.

Treatments:

Pembrolizumab